Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 21:9:867873.
doi: 10.3389/fcvm.2022.867873. eCollection 2022.

Genetics of Anthracycline-Associated Cardiotoxicity

Talal Khalid Al-Otaibi  1 , Benjamin Weitzman  1 , Usman A Tahir  1 , Aarti Asnani  1
Affiliations
Review

Genetics of Anthracycline-Associated Cardiotoxicity

Talal Khalid Al-Otaibi et al. Front Cardiovasc Med. .

Abstract

Anthracyclines are a major component of chemotherapies used in many pediatric and adult malignancies. Anthracycline-associated cardiotoxicity (ACT) is a dose-dependent adverse effect that has substantial impact on morbidity and mortality. Therefore, the identification of genetic variants associated with increased risk of ACT has the potential for significant clinical impact to improve patient care. The goal of this review is to summarize the current evidence supporting genetic variants associated with ACT, identify gaps and limitations in current knowledge, and propose future directions for incorporating genetics into clinical practice for patients treated with anthracyclines. We will discuss mechanisms of ACT that could be illuminated by genetics and discuss clinical applications for the cardiologist/cardio-oncologist.

Keywords: anthracycline; anthracycline associated cardiotoxicity; cardio-oncology; genetic testing; genetics.

PubMed Disclaimer

Conflict of interest statement

AA has consulted for Sanofi and AstraZeneca, serves as an advisory board member for Cytokinetics, and serves as the principal investigator for a sponsored research agreement with Genentech. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
A Venn diagram of overlapping genes implicated in ACT and other types of cardiomyopathies.
See this image and copyright information in PMC

References

    1. van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. (2006) 42:3191–8. 10.1016/j.ejca.2006.08.005 - DOI - PubMed
    1. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. (2010) 10:337. 10.1186/1471-2407-10-337 - DOI - PMC - PubMed
    1. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the american society of echocardiography and the european association of cardiovascular imaging. J Am Soc Echocardiogr. (2014) 27:911–39. - PubMed
    1. Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. (2015) 47:1079–84. 10.1038/ng.3374 - DOI - PMC - PubMed
    1. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. (2012) 30:1422–8. 10.1200/JCO.2010.34.3467 - DOI - PubMed

LinkOut - more resources